3 Spectacular High-Yield Dividend Stocks to Buy in November

Core Viewpoint - High dividend yields can be misleading, but certain stocks like AbbVie, Gilead Sciences, and Pfizer present solid investment opportunities due to their strong fundamentals and consistent dividend growth [1][2]. AbbVie - AbbVie offers a 3.2% dividend yield, which is above average, and has consistently increased its dividend for years [3][4]. - The company announced a new quarterly dividend of $1.64 per share, reflecting a 5.8% increase, and has raised its quarterly dividend by 310% since its spin-off from Abbott Laboratories in 2013 [4][5]. - AbbVie generated $41.2 billion in sales over the past nine months, a 3% increase year-over-year, despite facing challenges with its top-selling drug Humira, which saw a 34% decline in sales this year [6][7]. Gilead Sciences - Gilead Sciences has a forward dividend yield of over 3.4%, significantly higher than the S&P 500 average of 1.3%, and has increased its dividends by 22.2% since late 2019 [9][10]. - The company has maintained revenue stability through its COVID-19 therapy Veklury and remains a leader in the HIV drug market with a 49% market share [10][11]. - Gilead is focusing on oncology, with over half of its 52 clinical programs dedicated to new cancer drugs or label expansions, indicating a strong pipeline for future growth [11][12]. Pfizer - Pfizer's forward dividend yield is currently at 6.1%, with a strong focus on maintaining and growing its dividend [13][14]. - The stock trades at approximately 9.2 times forward earnings, which is about half of the S&P 500 healthcare sector's forward earnings multiple [14]. - Despite potential challenges from patent expirations, Pfizer has a promising lineup of drugs and a robust pipeline with 108 programs in clinical development, including 30 in late-stage testing [15][16].